Evidence map›Paper›PMID 38755516›Full record

SynthesisInternational journal of clinical oncology2024

Effectiveness and safety of granulocyte colony-stimulating factor priming regimen for acute myeloid leukemia: A systematic review and meta-analysis of the Clinical Practice Guideline for the use of G-CSF 2022 from the Japan Society of Clinical Oncology.

Yuho Najima, Tomoya Maeda, Yutaro Kamiyama, Shinji Nakao, Yukinori Ozaki, Hiroshi Nishio, Kenji Tsuchihashi, Eiki Ichihara, Yuji Miumra, Makoto Endo and 17 more

Abstract readSystematic ReviewMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in International journal of clinical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Yuho NajimaHematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-8-22 Honkomagome, Bunkyo-Ku, Tokyo, 113-8677, Japan. yuhonajima@gmail.com.
Tomoya MaedaDepartment of Hemato-Oncology, Saitama Medical University International Medical Center, Saitama, Japan.
Yutaro KamiyamaDepartment of Clinical Oncology/Hematology, The Jikei University School of Medicine, Tokyo, Japan.
Shinji NakaoDepartment of Hematology, Faculty of Medicine, Institute of Medical Pharmaceutical and Health Sciences, Kanazawa University, Ishikawa, Japan.
Yukinori OzakiDepartment of Breast Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Hiroshi NishioDepartment of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan.
Kenji TsuchihashiDepartment of Hematology, Oncology and Cardiovascular Medicine, Fukuoka, Japan.
Eiki IchiharaCenter for Clinical Oncology, Okayama University Hospital, Okayama, Japan.
Yuji MiumraDepartment of Medical Oncology, Toranomon Hospital, Tokyo, Japan.
Makoto EndoDepartment of Orthopaedic Surgery, Kyushu University, Fukuoka, Japan.
Dai MaruyamaDepartment of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Tetsuhiro YoshinamiDepartment of Breast and Endocrine Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan.
Nobuyuki SusumuDepartment of Obstetrics and Gynecology, International University of Health and Welfare Narita Hospital, Chiba, Japan.
Munetaka TakekumaDepartment of Gynecology, Shizuoka Cancer Center, Shizuoka, Japan.
Takashi MotohashiDepartment of Obstetrics and Gynecology, Tokyo Women's Medical University Hospital, Tokyo, Japan.
Mamoru ItoDepartment of Hematology, Oncology and Cardiovascular Medicine, Fukuoka, Japan.
Eishi BabaDepartment of Oncology and Social Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Nobuaki OchiDepartment of General Internal Medicine 4, Kawasaki Medical School, Okayama, Japan.
Toshio KuboDepartment of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
Keita UchinoDepartment of Medical Oncology, NTT Medical Center Tokyo, Tokyo, Japan.
Takahiro KimuraDepartment of Urology, The Jikei University School of Medicine, Tokyo, Japan.
Shinobu TamuraDepartment of Hematology/Oncology, Wakayama Medical University, Wakayama, Japan.
Hitomi NishimotoDepartment of Nursing, Okayama University Hospital, Okayama, Japan.
Yasuhisa KatoDepartment of Drug Information, Faculty of Pharmaceutical Sciences, Shonan University of Medical Sciences, Kanagawa, Japan.
Atsushi SatoDepartment of Medical Oncology, Hirosaki University Graduate School of Medicine, Aomori, Japan.
Toshimi TakanoDepartment of Breast Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Shingo YanoDepartment of Clinical Oncology/Hematology, The Jikei University School of Medicine, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe outcomes of relapsed or refractory acute myeloid leukemia (AML) remain poor. Although the concomitant use of granulocyte colony-stimulating factor (G-CSF) and anti-chemotherapeutic agents has been investigated to improve the antileukemic effect on AML, its usefulness remains controversial. This study aimed to investigate the effects of G-CSF priming as a remission induction therapy or salvage chemotherapy.

methodsWe performed a thorough literature search for studies related to the priming effect of G-CSF using PubMed, Ichushi-Web, and the Cochrane Library. A qualitative analysis of the pooled data was performed, and risk ratios (RRs) with confidence intervals (CIs) were calculated and summarized.

resultsTwo reviewers independently extracted and accessed the 278 records identified during the initial screening, and 62 full-text articles were assessed for eligibility in second screening. Eleven studies were included in the qualitative analysis and 10 in the meta-analysis. A systematic review revealed that priming with G-CSF did not correlate with an improvement in response rate and overall survival (OS). The result of the meta-analysis revealed the tendency for lower relapse rate in the G-CSF priming groups without inter-study heterogeneity [RR, 0.91 (95% CI 0.82-1.01), p = 0.08; I

conclusionsG-CSF priming in combination with intensive remission induction treatment is not universally effective in patients with AML. Further studies are required to identify the patient cohort for which G-CSF priming is recommended.

Indexed as

Granulocyte Colony-Stimulating FactorLeukemia, Myeloid, AcuteAntineoplastic Combined Chemotherapy ProtocolsHumansJapanPractice Guidelines as TopicRemission InductionSalvage TherapyGranulocyte Colony-Stimulating FactorAcute myeloid leukemiaG-CSFMeta-analysisPriming effect

Identifiers

PMID38755516

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.